EBV antibody tertile category | Cases N (%) 119 | Seropositive controls N (%) 105 | ORadj* (95% CI) | HRadj** (95% CI) |
---|---|---|---|---|
Low EBNA-1 | 43 (36%) | 34 (32%) | 0.97 (0.52 - 1.82) | 0.93 (0.45 -1.98) |
High VCA | 42 (35%) | 45 (43%) | 0.87 (0.45 - 1.69) | 1.10 (0.50 - 2.35) |
Low EBNA-1/high VCA | 5 (4%) | 6 (6%) | 0.55 (0.15 - 2.00) | 0.53 (0.12 - 2.29) |
EBNA-1/VCA category | ||||
Low/High Low/Not high Not low/High Not low/not high | 5 (4%) 38 (32%) 37 (31%) 39 (33%) | 6 (6%) 28 (27%) 39 (37%) 32 (30%) | 0.56 (0.14 - 2.18) 1.08 (0.52 - 2.25) 0.98 (0.46 - 2.09) Reference | 0.62 (0.13 - 3.10) 1.20 (0.49 - 2.92) 1.23 (0.54 - 2.84) Reference |
EBV antibody tertile category | Seropositive controls N (%) 105 | Seronegative controls N (%) 155 | ORadj† (95% CI) | HRadj‡ (95% CI) |
Low EBNA-1 | 34 (32%) | 52 (34%) | 0.98 (0.56 - 1.70) | 1.04 (0.60 - 1.80) |
High VCA | 45 (43%) | 42 (27%) | 1.90 (1.04 - 3.47) | 1.88 (1.04 - 3.40) |
Low EBNA-1/high VCA | 6 (6%) | 6 (4%) | 1.53 (0.47 -5.02) | 1.00 (0.33 - 3.07) |
EBNA-1/VCA category | ||||
Low/High Not low/High Low/Not high Not low/not high | 6 (6%) 28 (27%) 39 (37%) 32 (30%) | 6 (4%) 46 (30%) 36 (23%) 67 (42%) | 2.11 (0.61 - 7.30) 1.18 (0.61 - 2.27) 2.02 (1.00 - 4.07) Reference | 1.76 (0.52 - 5.93) 1.43 (0.74 - 2.78) 2.20 (1.14 - 4.24) Reference |